Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02032901 · ClinicalTrials.gov registry record · Phase 3
Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV
A Phase 3 study of Hepatitis C, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 173
- Enrollment target
- 20
- Study locations
NCT02032901 is a Phase 3 study of Hepatitis C that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 173 participants, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT02032901, a Phase 3 study of Hepatitis C, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 173 participants
- Enrollment target
- 20
- Study locations
Study Summary
To study the combination of Daclatasvir and Sofosbuvir for the treatment of hepatitis C virus (HCV) Genotype 3 infection
Conditions Studied
Interventions
- DRUG Sofosbuvir
- DRUG Daclatasvir
Study Locations (20)
California
- Scripps Clinic - La Jolla
- Peter J Ruane MD Inc - Los Angeles
- National Research Institute - Los Angeles
- Anthony M. Mills MD Inc - Los Angeles
- Huntington Medical Research Institutes - Pasadena
- Precision Research Institute, LLC - San Diego
- Medical Associates Research Group - San Diego
- Quest Clinical Research - San Francisco
Florida
- Midland Florida Clinical Research Center, LLC - DeLand
- University of Florida Hepatology Research - Gainesville
Georgia
- Atlanta Gastroenterology Associates - Atlanta
- Gastrointestinal Specialists Of Georgia - Marietta
Maryland
- Mercy Medical Center, Inc. - Baltimore
- Digestive Disease Associates, P.A. - Baltimore
New York
- North Shore University Hospital - Manhasset
- Premier Medical Group Of The Hudson Valley, Pc - Poughkeepsie
Illinois
- Dupage Medical Group - Downers Grove
Missouri
- Kansas City Research Institute - Kansas City
New Mexico
- Southwest Care Center - Santa Fe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02032901
The ClinicalTrials.gov registry entry for NCT02032901 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (91% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Sofosbuvir is the first listed.
NCT02032901 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT02032901 about?
NCT02032901 is a clinical study titled "Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV". To study the combination of Daclatasvir and Sofosbuvir for the treatment of hepatitis C virus (HCV) Genotype 3 infection
What is the current status of trial NCT02032901?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 173 participants. The study started on 2014-01. Estimated completion is 2014-12.
What conditions does trial NCT02032901 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT02032901?
The interventions under investigation include: Sofosbuvir (DRUG), Daclatasvir (DRUG).
Who is sponsoring clinical trial NCT02032901?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02032901 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)
COMPLETED · Phase 3
-
SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection
COMPLETED · Phase 3
-
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy
COMPLETED · Phase 3
-
Hepatitis C Antiviral Resistance in African-Americans
COMPLETED · Phase 3
-
Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
COMPLETED · Phase 3
-
An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.